Cytomegalovirus following stem cell transplantation: From pharmacologic to immunologic therapy

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 4, 2004, Pages 559-573

  Peggs, Karl S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Aciclovir; Cellular therapy; Cidofovir; Cytomegalovirus; Foscarnet; Ganciclovir; Immune responses; Transplantation

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; FOSCARNET SODIUM; GANCICLOVIR; GLYCOPROTEIN B; IMMUNOGLOBULIN; PROBENECID; RECOMBINANT GROWTH FACTOR; SYNAPTOTAGMIN; VALACICLOVIR; VALGANCICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLITIS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DNA VIRUS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG USE; ELECTROLYTE DISTURBANCE; GRAFT VERSUS HOST REACTION; HEADACHE; HEPATITIS; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMONIA; REVIEW; TASTE DISORDER; TISSUE INJURY; VIRUS LATENCY; VIRUS REACTIVATION;

EID: 4444295107     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.4.559     Document Type: Review

References (99)

1. Sissons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus infection. J. Infect. 44(2), 78-83 (2002).
2. Zaia JA, Sissons JG, Riddell S et al. Status of cytomegalovirus prevention and treatment in 2000. Hematology (Am. Soc. Hematol. Educ. Program) 339-355 (2000).
3. Peggs KS, Verfuerth S, Pizzey A et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. Biol. Blood Marrow Transplant. 9(3), 198-205 (2003).
4. Holmberg LA, Boeckh M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94(12), 4029-4035 (1999).
5. Neiman PE, Reeves W, Ray G et al. A prospective analysis of interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J. Infect. Dis. 136(6), 754-767(1977).
6. Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99(6), 1978-1985 (2002).
7. Junghanss C, Storb R, Maris MB et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after nonmyeloablative allogeneic stem cell transplantation. Br. J. Haematol. 123(4), 662-670 (2003).
8. Lonnqvist B, Ringden O, Ljungman P, Wahren B, Gahrton G. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br. J. Haematol. 63(4), 671-679 (1986).
9. Nachbaur D, Bonatti H, Oberaigner W et al. Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet 358(9288), 1157-1159 (2001).
10. Remberger M, Ringden O. Survival after bone-marrow transplantation. Lancet 359(9309), 888 (2002).
11. Cwynarski K, Craddock C, Cobbold M, Apperley J, Goldman J. Survival after bone-marrow transplantation. Lancet 359(9309), 887-888 (2002).
12. Szydlo R. Survival after bone-marrow transplantation. Lancet 359(9309), 888-889(2002).
13. Gandhi MK, Wills MR, Okecha G et al. late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T-cells following allogeneic hemopoietic stem cell transplantation. Blood 102(9), 3427-3438 (2003).
14. Soderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Moller E. Cytomegalovirus-induced CD13-specific autoimmunity - a possible cause of chronic graft versus host disease. Transplantation 61(4), 600-609 (1996).
15. Rapp M, Messerle M, Buhler B, Tannheimer M, Keil GM, Koszinowski UH. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J. Virol. 66(7), 4399-4406 (1992).
16. + memory T-cell response to cytomegalovirus.J. Immunol. 167(3), 115-1163 (2001).
17. Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol. Ther. 98(3), 269-297 (2003).
18. +-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 73(10), 8179-8184 (1999).
19. +-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 77(9 , 5226-5240 (2003).
20. Kern F, Bunde T, Faulhaber N et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T-cell repertoire in CMV-exposed individuals. J. Infect. Dis. 185(12), 1709-1716(2002).
21. Gyulai Z, Endresz V, Burian K et al. Cytotoxic T-lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-exon4, gB, pp150 and pp28 in healthy individuals: re-evaluation of prevalence of IE1-specific CTLs. J. Infect. Dis. 181(5), 1537-1546(2000).
22. Pass RF. Cytomegalovirus. In: Fields Virology. Knipe D, Howley P(Eds), Lippincott, Williams and Wilkins, PA, USA, 2675-2705 (2001).
23. + T-cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality and phenotype. J. Infect. Dis. 185(8), 1025-1034 (2002).
24. Sester M, Sester U, Gartner B et al. Sustained high frequencies of specific CD4 T-cells restricted to a single persistent virus. J. Virol. 76(8), 3748-3755(2002).
25. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78(5), 1373-1380 (1991).
26. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320(26), 1731-1735 (1989).
27. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 13(4), 458-464 (2001).
28. Brown MG, Scalzo AA, Matsumoto K, Yokoyama WM. The natural killer gene complex: a genetic basis for understanding natural killer cell function and innate immunity. Immunol. Rev. 155, 53-65 (1997).
29. Lopez-Botet M, Angulo A, Guma M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens 63(3), 195-203 (2004).
30. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333(16), 1038-1044 (1995).
31. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Ann. Rev. Immunol. 18, 861-926 (2000).
32. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbiol. 8(9), 410-418 (2000).
33. Mocarski ES Jr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 10(7), 332-339 (2002).
34. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383(6602), 720-722 (1996).
35. Lopez-Botet M, Llano M, Ortega M. Human cytomegalovirus and natural killer-mediated surveillance of HLA class I expression: a paradigm of host-pathogen adaptation. Immunol. Rev. 181, 193-202 (2001).
36. Tomasec P, Braud VM, Rickards C et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287(5455), 1031 (2000).
37. Ulbrecht M, Martinozzi S, Grzeschik M et al. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J. Immunol. 164(10), 5019-5022 (2000).
38. Cosman D, Fanger N, Borges L et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7(2), 273-282 (1997).
39. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 99(8), 2913-2921 (2002).
40. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr. Opin. Immunol. 14(3), 306-311 (2002).
41. Cosman D, Mullberg J, Sutherland CL et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14(2), 123-133 (2001).
42. Dunn C, Chalupny NJ, Sutherland CL et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J. Exp. Med. 197(11), 1427-1439 (2003).
43. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nature Rev. Immunol. 3(1), 36-50 (2003).
44. Cwynarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97(5), 1232-1240 (2001).
45. Aubert G, Hassan-Walker AF, Madrigal JA et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J. Infect. Dis. 184(8), 955-963(2001).
46. + T-lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98(5), 1358-1364 (2001).
47. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 257(5067), 238-241 (1992).
48. Hebart H, Daginik S, Stevanovic S et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 99(10), 3830-3837 (2002).
49. Griffiths PD, Cope AV, Hassan-Walker AF, Emery VC. Diagnostic approaches to cytomegalovirus infection in bone marrow and organ transplantation. Transpl. Infect. Dis. 1(3), 179-186 (1999).
50. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11(3), 533-554 (1998).
51. Pancholi P, Wu F, Della-Latta P. Rapid detection of cytomegalovirus infection in transplant patients. Expert Rev. Mol. Diagn. 4(2), 231-242 (2004).
52. Gerna G, Percivalle E, Baldanti F et al. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J. Virol. 74(12), 5629-5638 (2000).
53. Boivin G, Olson CA, Quirk MR, St Cyr SM, Jordan MC. Quantitation of human cytomegalovirus glycoprotein H gene in cells using competitive PCR and a rapid fluorescence-based detection system. J. Virol. Methods 51(2-3), 329-342 (1995).
54. Shinkai M, Spector SA. Quantitation of human cytomegalovirus (HCMV) DNA in cerebrospinal fluid by competitive PCR in AIDS patients with different HCMV central nervous system diseases. Scand. J. Infect. Dis. 27(6), 559-561 (1995).
55. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Meth. Appl. 4(6), 357-362 (1995).
56. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 22(1), 176-181 (1997).
57. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 6(10), 986-994 (1996).
58. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22(1), 130-138 (1997).
59. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355(9220), 2032-2036 (2000).
60. Walmsley S, O'Rourke K, Mortimer C, Rachlis A, Fong I, Mazzulli T. Predictive value of cytomegalovirus (CMV) antigenemia and digene hybrid capture DNA assays for CMV disease in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 27(3), 573-581 (1998).
61. Gerna G, Baldanti F, Middeldorp J, Lilleri D. Use of CMV transcripts for monitoring of CMV infections in transplant recipients. Int. J. Antimicrob. Agents 16(4), 455-460 (2000).
62. Gerna G, Lilleri D, Baldanti F et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 101(12), 5053-5060 (2003).
63. Naesens L, De Clercq E. Recent developments in herpesvirus therapy. Herpes 8(1), 12-16 (2001).
64. Reusser P. Oral valganciclovir. a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin. Investig. Drugs. 10(9), 1745-1753 (2001).
65. Reusser P, Cordonnier C, Einsele H et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 17(5), 813-817 (1996).
66. Reusser P, Einsele H, Lee J et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99 (4), 1159-1164 (2002).
67. Ljungman P, Deliliers GL, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 97(2), 388-392(2001).
68. Bacigalupo A, Bregante S, Tedone E et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 62(3), 376-380(1996).
69. Chulay J, Biron K, Wang L et al. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv. Exp. Med. Biol. 458, 129-134 (1999).
70. Emanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109(10), 777-782(1988).
71. Ljungman P, Engelhard D, Link H et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin. Infect Dis. 14(4), 831-835 (1992).
72. Reed EC, Bowden RA, Dandliker PS, Gleaves CA, Meyers JD. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J. Infect. Dis. 156(4), 641-645 (1987).
73. Hakki M, Riddell SR, Storek J et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy and subclinical reactivation. Blood 102(8), 3060-3067 (2003).
74. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118(3), 173-178 (1993).
75. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83(7), 1971-1979 (1994).
76. Prentice HG, Gluckman E, Powles F et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 343(8900), 749-753 (1994).
77. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin. Infect. Dis. 36(6), 749-758 (2003).
78. Ljungman P, de la Camara R, Milpied N et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99(8), 3059-3056 (2002).
79. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N. Engl. J. Med. 325(23), 1601-1607 (1991).
80. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88(10), 4063-4071(1996).
81. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 93(5), 1781-1782 (1999).
82. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86(7), 2815-2820 (1995).
83. Peggs KS, Preiser W, Kottaridis PD et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br. J. Haematol. 111(3), 782-790 (2000).
84. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99(12), 4357-4363 (2002).
85. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load and outcomes. Blood 97(4), 867-874(2001).
86. Craddock C, Szydlo RM, Dazzi F et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft versus host disease prophylaxis. Br. J. Haematol. 112(1), 228-236 (2001).
87. Reddehase MJ, Weiland F, Munch K, Jonjic S, Luske A, Koszinowski UH. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J. Virol. 55(2), 264-273(1985).
88. Peggs KS, Mackinnon S. Clinical trials with CMV-specific T-cells. Cytotherapy 4(1), 21-28 (2002).
89. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330(17), 1185-1191 (1994).
90. Kernan NA, Collins NH, Juliano L, Cartagena T, DuPont B, O'Reilly RJ. Clonable T-lymphocytes in T-cell-depleted bone marrow transplants correlate with development of graft-vs.-host disease. Blood 68(3), 770-773 (1986).
91. Greenberg PD, Reusser P, Goodrich JM, Riddell SR. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T-cell clones expanded in vitro. Ann. NY Acad. Sci. 636,184-195 (1991).
92. Keenan RD, Ainsworth J, Khan N et al. Purification of cytomegalovirus-specific CD8 T-cells from peripheral blood using HLA-peptide tetramers. Br. J. Haematol. 115(2), 428-434 (2001).
93. + T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 103(9), 3565-3572 (2004).
94. Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T-lymphocytes. Nature Med. 2(5), 551-555 (1996).
95. Peggs KS, Verfuerth S, Pizzey A et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362(9393), 1375-1377 (2003).
96. Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T-cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99(11), 3916-3922 (2002).
97. Berencsi K, Gyulai Z, Gonczol E et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T-cell responses in human CMV-seronegative subjects. J. Infect. Dis. 183(8), 1171-1179 (2001).
98. Pepperl S, Munster J, Mach M, Harris JR, Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol. 74(13), 6132-6146 (2000).
99. Endresz V, Burian K, Berencsi K et al. Optimization of DNA immunization against human cytomegalovirus. Vaccine 19(28-29), 3972-3980(2001).